0
0
The European Medicines Agency (EMA) has announced a significant expansion in the recommended use of the dapivirine vaginal ring, a flexible silicone device designed to reduce the risk of HIV-1 infection in women. The ring, which is inserted into the vagina for a period of 28 days and then replaced, is now advised for use in females from 16 years of age, following a positive review of additional safety and efficacy data.
Previously, the ring had been approved for women 18 years and older, especially for those unable to use oral pre-exposure prophylaxis (PrEP) medicines. The EMA’s Committee for Medicinal Products for Human Use (CHMP) highlighted that while initial uncertainties existed regarding the risk of resistance and benefits in younger women, further studies demonstrated moderate effectiveness in lowering HIV-1 infection risk through vaginal intercourse, with manageable side effects.
The dapivirine ring is the first long-acting technology approved for HIV prevention in women and is intended for use primarily outside the European Union. The recommendation was made under the EU-Medicines for All (EU-M4All) regulatory procedure, which enables the EMA to collaborate with the World Health Organization (WHO) to support global regulatory capacity and improve access to essential medicines in low- and middle-income countries.
The ring works by slowly releasing the antiretroviral drug dapivirine into the vagina, providing continuous protection for a month. It is designed as a discreet, user-controlled option, which is particularly valuable in regions with high HIV stigma or limited access to healthcare. The device does not prevent other sexually transmitted infections or unintended pregnancy and should be used alongside condoms for comprehensive protection.
This recent extension of indication marks a step forward in expanding HIV prevention options for adolescent girls and young women, a group that remains disproportionately affected by HIV in many parts of the world.
Disclaimer:
This article is based on information from the European Medicines Agency and published medical sources. It does not constitute medical advice. Readers are encouraged to consult healthcare professionals for guidance on HIV prevention and treatment options. The dapivirine vaginal ring is not a substitute for condoms or other barrier methods and does not prevent all sexually transmitted infections or pregnancy. Always follow the recommendations of your healthcare provider regarding HIV prevention strategies.
